Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421629 | 1.00 | TSHR (0.41) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL1865400 | 1.00 | TSHR (0.41) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL1133379 | 0.85 | GRIK1 (0.46) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL8596279 | 0.85 | GRIK1 (0.37) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2361609 | 0.80 | GRIK1 (0.34) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2361611 | 0.80 | GRIK1 (0.34) | TSHRGRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL23688391 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL8020514 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL6530499 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 | |
| SCHEMBL8017237 | 0.79 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | LABORATOIRES SERONO S.A. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| WO-1994026749-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5086062-A | Inhibitors of lipoxygenase and-or cyclooxygenase enzymes | PFIZER INC. (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | TSHR 3346/4885GRIK1 4070/4885GRIK2 4324/4885 |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | TSHR 1756/4885GRIK1 3847/4885GRIK2 4204/4885 |
| US-20100280018-A1 | Derivatives Of Hydroxamic Acid As Metalloproteinase Inhibitors | MMP3, MMP1, MMP13 | TSHR 3477/4885GRIK1 786/4885GRIK2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.